{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:05:34Z","timestamp":1792425934365,"version":"4.5.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"am","delay-in-days":281,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001665","name":"ANR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.semarthrit.2022.152087","type":"journal-article","created":{"date-parts":[[2022,8,27]],"date-time":"2022-08-27T20:21:43Z","timestamp":1661631703000},"page":"152087","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Placebo response in Raynaud's Phenomenon clinical trials: The prominent role of regression towards the mean"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4475-1626","authenticated-orcid":false,"given":"Matthieu","family":"Roustit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Jullien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9ment","family":"Jambon-Barbara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Goudon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Luc","family":"Cracowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152087_bib0001","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","article-title":"The pathogenesis, diagnosis and treatment of Raynaud phenomenon","volume":"8","author":"Herrick","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0002","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis Rheumatism"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0003","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/ije\/dyh299","article-title":"Regression to the mean: what it is and how to deal with it","volume":"34","author":"Barnett","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0004","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/j.jacc.2016.07.775","article-title":"Regression to the Mean in SYMPLICITY HTN-3: implications for Design and Reporting of Future Trials","volume":"68","author":"Pocock","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0005","doi-asserted-by":"crossref","first-page":"m1668","DOI":"10.1136\/bmj.m1668","article-title":"Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice","author":"Kaptchuk","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0006","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1002\/art.40307","article-title":"Editorial: clinical Trials in Raynaud's Phenomenon: a Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames)","volume":"69","author":"Seibold","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0007","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/M18-0517","article-title":"On-Demand Sildenafil as a Treatment for Raynaud Phenomenon: a Series of n -of-1 Trials","volume":"169","author":"Roustit","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0008","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1016\/S2665-9913(19)30079-7","article-title":"Comparative efficacy and safety of treatments for secondary Raynaud's phenomenon: a systematic review and network meta-analysis of randomised trials","volume":"1","author":"Khouri","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0009","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1136\/ard.2009.107706","article-title":"The minimally important difference and patient acceptable symptom state for the Raynaud's condition score in patients with Raynaud's phenomenon in a large randomised controlled clinical trial","volume":"69","author":"Khanna","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.therap.2019.03.002","article-title":"French translation and linguistic validation of the Raynaud's condition score","volume":"74","author":"Khouri","year":"2019","journal-title":"Therapie"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.sleep.2011.03.008","article-title":"Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs","volume":"12","author":"McCall","year":"2011","journal-title":"Sleep Med"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0140-6736(96)90410-9","article-title":"How to deal with regression to the mean in intervention studies","volume":"347","author":"Yudkin","year":"1996","journal-title":"Lancet North Am Ed"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0013","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","article-title":"Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: a Randomized, Placebo-Controlled, Phase II Study","volume":"69","author":"Denton","year":"2017","journal-title":"Arthritis Rheumatol (Hoboken, NJ)"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0014","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/art.40123","article-title":"The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial","volume":"69","author":"Bello","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0015","article-title":"Topical Nitroglycerine (NTG) Vs Matching Vehicle in Secondary Raynaud Phenomenon (RP) \u2013 a Double-Blind Crossover Study of Subjective and Physiologic Responses to Controlled Cold Challenge","author":"Khanna","year":"2017","journal-title":"ACR Meeting Abstracts"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0016","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13196","article-title":"Assessment of Placebo Response in Objective and Subjective Outcome Measures in Rheumatoid Arthritis Clinical Trials","volume":"3","author":"Vollert","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0017","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1474-4422(04)00908-1","article-title":"Overt versus covert treatment for pain, anxiety, and Parkinson's disease","volume":"3","author":"Colloca","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.semarthrit.2022.152087_bib0018","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jclinepi.2016.03.028","article-title":"N-of-1 trials to enhance patient outcomes: identifying effective therapies and reducing harms, one patient at a time","volume":"76","author":"Vohra","year":"2016","journal-title":"J Clin Epidemiol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722200138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004901722200138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:08:13Z","timestamp":1758733693000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004901722200138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":18,"alternative-id":["S004901722200138X"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152087","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Placebo response in Raynaud's Phenomenon clinical trials: The prominent role of regression towards the mean","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"152087"}}